Explore molecular identities and constituents associated with this field of study.
Explore 9 references →Compound reference
Explore the reference for each compound.
TirzepatideTirzepatide combines GIP and GLP-1 receptor activity. Human trials have measured substantial weight reduction with specific medicines and treatment plans; individual outcomes and risks vary, and these results do not establish equivalence of other preparations.
Read referenceRetatrutideRetatrutide combines GIP, GLP-1 and glucagon receptor activity. The cited phase II trial reported weight reductions that motivate further clinical study; its findings concern a particular investigational treatment and follow-up period.
Read reference5-amino-1MQResearchers are exploring whether inhibiting NNMT could influence fat storage and cellular energy use. The potential application is metabolic health; the evidence discussed here is preclinical, so human weight-loss benefits remain unestablished.
Read referenceAdipotideAdipotide explores a different approach to body composition: targeting the blood supply of fat tissue. Preclinical findings prompted interest in metabolic applications, but kidney toxicity is an important unresolved limitation.
Read referenceAICARAICAR is studied for activating AMPK, a cellular energy sensor. Researchers examine how this pathway changes glucose uptake and the use of fats for energy; these mechanisms are not proof of improved human performance.
Read referenceAOD9604AOD9604 was designed to explore the fat-metabolism functions of a growth-hormone fragment. Human research has examined selected safety markers; demonstrating meaningful weight-management benefits is a separate question.
Read referenceCagrilintideCagrilintide targets amylin-related pathways involved in fullness and food intake. Human research has measured weight reduction, with the potential application and tolerability depending on the treatment and population studied.
Read referenceSemaglutideSemaglutide acts on the GLP-1 pathway involved in appetite and glucose regulation. Large human trials of defined medicines have demonstrated weight reduction in specified populations; the study summaries explain the magnitude, duration and limitations.
Read referenceSurvodutideSurvodutide combines glucagon and GLP-1 receptor activity. Research explores weight regulation and metabolic outcomes; the cited phase II findings provide context for its potential rather than a prediction for an individual.
Read reference